Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is positioned favorably within the clinical-stage biopharmaceutical sector focused on neurodegenerative diseases, leveraging proprietary technology platforms to advance a promising pipeline. The substantial 20-fold increase in antibodies associated with its PD active immunotherapy ACI-7104.056, along with a strategic approach to drug delivery that mitigates potential adverse effects, underscores the potential efficacy and safety of its treatments. Furthermore, the potential for increased interest in the NLRP3 program, particularly contingent on positive results from the upcoming EVOKE trial in Alzheimer's Disease patients, enhances the company's growth prospects and investor attractiveness.

Bears say

AC Immune SA recorded a net operating loss of CHF 16.2 million, highlighting ongoing financial challenges. The company is exposed to significant risks inherent in the biopharmaceutical industry, including potential adverse outcomes from clinical trials, regulatory uncertainties, and the pressures of navigating complex and price-sensitive commercial markets. These factors contribute to a persistently negative outlook on the company's financial stability and growth prospects.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.